Remove Epilepsy Remove Events Remove Treatment
article thumbnail

IDPH approves four new conditions for medical cannabis treatment

Illinois News Joint

Providers are now able to begin certifying patients with those conditions for treatment with medical cannabis. To find cannabis-friendly events in Illinois, visit here. The post IDPH approves four new conditions for medical cannabis treatment appeared first on Illinois News Joint. For Illinois News Joint reviews, visit here.

article thumbnail

Effectiveness Of CBD: Is It A Safe Treatment For Seizures And Epilepsy?

Cannabis Law Report

CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. Seizures and epilepsy are serious medical conditions. Epilepsy is a central nervous system disorder that involves the brain making people more susceptible to recurrent unprovoked seizures. billion by the year 2028.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome

Cannabis Law Report

SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110. The primary safety objective of the study will be to assess absolute and relative frequencies of Serious Adverse Events (SAEs) for the whole population and separately for SCI-110 and placebo groups. 1] [link]. [2]

article thumbnail

Realm of Caring Appoints Research Director to Oversee Groundbreaking Cannabis Data Registry and Medical Studies

Cannabis Law Report

and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 81
article thumbnail

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Cannabis Law Report

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug. ” About The Study.

article thumbnail

CBD Market Report

Project CBD

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. US Food & Drug Administration website.

CBD 144
article thumbnail

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

Cannabis Law Report

Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder with Comorbid Lennox-Gastaut Syndrome: A Post-hoc Analysis from the Marigold Study. change in MMSF).